SavedAdd your journal

Journals / Cukurova Medical Journal / 2013 / Cilt: 38 - Sayı: 4

Comparison of Calcitonin and Pamidronate Treatments in Children with Osteogenesis Imperfecta

Ostegenezis İmperfekta Olan Çocuklarda Pamidronat ve Kalsitonin Tedavilerinin Karşılaştırılması

Neslihan Önenli MUNGAN
Fatih GÜRBÜZ
Eda MENGEN
Özden ÖZGÜR
Ali Kemal TOPALOGLU
Bilgin YÜKSEL
Pages
667–674
Publication Date
2013-12-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: Annual fracture rates decreased from 2.72 ± 0.80 to 0.40 ± 0.70 (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: The main objective of this study was to compare the treatments of calcitonin and pamidronate by clinical, biochemical, and radiological findings in children with osteogenesis imperfecta and evaluate the efficiency of pamidronate treatment.
📊
Key Findings & Data:Patients and methods: A total of 12 patients, aged 41±38 (1-120) months were studied.
💡
Conclusion & Impact:Results: Annual fracture rates decreased from 2.72 ± 0.80 to 0.40 ± 0.70 (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Osteogenezis imperfekta · kalsitonin · pamidronat

Abstract

Purpose: The main objective of this study was to compare the treatments of calcitonin and pamidronate by clinical, biochemical, and radiological findings in children with osteogenesis imperfecta and evaluate the efficiency of pamidronate treatment. Patients and methods: A total of 12 patients, aged 41±38 (1-120) months were studied. Group 1 was consisted of six patients who had received intranasal calcitonin at a dosage of 4-6 U/kg three times a week before switching to pamidronate treatment. Group 2 was also consisted of six patients who had received only pamidronate infusion at a dosage of 0.5-2 mg/kg every two months. Results: Annual fracture rates decreased from 2.72 ± 0.80 to 0.40 ± 0.70 (p

Özet

Amaç: Bu çalışmanın temel amacı osteogenezis imperfekta olan çocuklarda klinik, biyokimyasal ve radyolojik bulgular ile pamidronat ve kalsitonin tedavisinin karşılaştırılması ve pamidronat tedavisinin etkinliğinin değerlendirilmesidir. Materyal ve Metod: Yaşları 41±38 (1-120) ay arasında değişen toplam 12 hasta çalışmaya alındı. Grup 1 pamidronat tedavisine geçmeden önce 4-6 U/kg haftada üç defa intranazal kalsitonin tedavisi alan altı hasta oluşturdu. Grup 2, iki ayda bir sadece tek doz 0.5-2 mg/kg dozunda pamidronat alan altı hasta idi. Bulgular: Yıllık kırık oranları Grup 1"de 2.72 ± 0.80"den 0.40 ± 0.70"e (p

🔖

Cite This Article

MUNGAN, N. Ö., GÜRBÜZ, F., MENGEN, E., ÖZGÜR, Ö., TOPALOGLU, A. K., YÜKSEL, B. (2013). Comparison of Calcitonin and Pamidronate Treatments in Children with Osteogenesis Imperfecta. Cukurova Medical Journal, Cilt: 38 - Sayı: 4, 667–674. https://ajindex.com/articles/57076

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Van Dijk FS, Pals G, van Rijn RR, Nikkels PG, Cobben JM: Classification of Osteogenesis Imperfecta revisited. Eur J Med Genet. 2010; 53: 1–5 Lindsay R. Modeling the benefits of pamidronate in children with osteogenesis imperfecta. J Clin Invest. 2002; 110: 1239-43.
  2. Rauch F, Travers R, Plotkin H, Glorieux FH. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest. 2002; 110: 1293-99.
  3. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998; 339: 986-7.
  4. Sillence DO, Senn A, Danks DM: Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979; 16: 101–16.
  5. Glorieux FH, Rauch F, Plotkin H et al: Type V osteogenesis imperfecta: a new form of brittle bone disease. J Bone Miner Res. 2000; 15: 1650–8.
  6. Glorieux FH, Ward LM, Rauch F, Lalic L, Roughly PJ, Travers R: Osteogenesis imperfecta type VI: a form of brittle bone disease with mineralization defect. J Bone Miner Res. 2002; 17: 30–7.
  7. Byers PH, Bonadio JF, Steinmann B. Osteogenesis imperfecta: update and perspective. Am J Med Genet. 1984; 17: 429-35.
  8. Barnes AM, Chang W, Morello R, Cabral WA, Weis M, et al: Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta. N Engl J Med. 2006; 355: 2757–64.
  9. Morello R, Bertin TK, Chen Y, Hicks J, Tonachini L, et al: CRTAP is required for prolyl 3-hydroxylation and mutations cause recessive osteogenesis imperfecta. Cell.2006; 127: 291–304.
  10. Cabral WA, Chang W, Barnes AM, Weis M, Scott MA, et al: Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta. Nat Genet. 2007; 39: 359–65.
  11. Van Dijk FS, Nesbitt IM, Zwikstra EH, Nikkels PG, Piersma SR, et al: PPIB mutations cause severe osteogenesis imperfecta. Am J Hum Genet. 2009;85: 521– Barnes AM, Carter EM, Cabral WA, Weis M, Chang W, et al: Lack of cyclophilin B in osteogenesis imperfecta with normal collagen folding. N Engl J Med. 2010; 362: 521–8.
  12. Christiansen HE, Schwarze U, Pyott SM, Al- Swaid A, Al Balwi M, et al: Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta. Am J Hum Genet. 2010; 86: 389–98.
  13. Alanay Y, Avaygan H, Camacho N, Utine GE, Boduroglu K, et al: Mutations in the gene encoding the RER protein FKBP65 cause autosomal rec